|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) ä¿ë_»ýµ¿BD °æ·ÂÀÚ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
1³â¡è |
ä¿ë½Ã |
08.03 |
|
|
¢ß´Ù»êÁ¦¾à |
Ç°Áúº¸ÁõÆÀ °è¾àÁ÷ ä¿ë
Ãæ³² ¾Æ»ê½Ã | °íµîÇб³ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
°æ·Â¹«°ü |
ä¿ë½Ã |
08.02 |
|
|
(ÁÖ)¹ÙÀÌ¿ÀÁö³ëÄÚ¸®¾Æ |
±â¾÷ºÎ¼³¿¬±¸¼Ò NGS»ç¾÷ºÎ À¯ÀüüºÐ¼® ¿¬±¸¿ø, ¼±ÀÓ¿¬±¸¿ø
¼¿ï ¼ºµ¿±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
2³â¡è |
ä¿ë½Ã |
07.30 |
|
|
PSI CRO Korea |
[PSI CRO Korea] CRA I/II
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
07.21 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA I/II (Lead Monitor Role)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
07.21 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Feasibility - Site ID Specialist
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
SSU |
2³â¡è |
ä¿ë½Ã |
07.21 |
|
|
PSI CRO Korea |
[PSI CRO Korea] CTA I/II, Sr.CTA
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CTA/CRC |
1³â¡è |
ä¿ë½Ã |
07.21 |
|
|
Çູ³ª·¡ ÁÖ½Äȸ»ç |
¿µ¾÷Á÷
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.09 |
|
|
ÁÖ½Äȸ»ç ÀνºÆÃÅͽº |
[Sexual Healthcare EVE] RA ä¿ë(¾à»ç ¿ì´ë)
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.09 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] Pharmacovigilance Team ÀÎÅÏ»ç¿ø ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.07 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Feasibility - Site ID Specialist
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
SSU |
2³â¡è |
ä¿ë½Ã |
06.03 |
|
|
PSI CRO Korea |
[PSI CRO Korea] CRA I/II
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
06.01 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA I/II (Lead Monitor Role)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
06.01 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] BD Assistant ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.27 |
|
|
¼Ò¾ß±×¸°ÅØ |
¼Ò¾ß±×¸°ÅØ Áø´Ü ÀÇ·á±â±â ¹× ¼Ò¸ðÇ° ±¹³»»ç¾÷ºÎ Á÷¿ø ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
»ý¸í°øÇÐ/¹ÙÀÌ¿À ¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.26 |
|